Log In
BCIQ
Print this Print this
 

Neoprofen (ibuprofen lysine)

  Manage Alerts
Collapse Summary General Information
Company H. Lundbeck A/S
DescriptionIbuprofen lysine injection
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard Indication Cardiovascular (unspecified)
Indication DetailsTreat patent ductus arteriosus (PDA)
Regulatory Designation U.S. - Orphan Drug (Treat patent ductus arteriosus (PDA))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$100.0M

$100.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/24/2012

$100.0M

$100.0M

0

Get a free BioCentury trial today